Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-07258669 in older adults at risk of malnutrition
NCT07086664Phase 1Terminated
- Sponsor
- Pfizer
- Start
- Aug 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, randomised, double-blind trial in unintentional weight loss comparing Placebo with PF-07258669 (2 arms). Primary endpoint: Treatment Emergent Adverse Events at 20 weeks. Started Aug 2025; status: terminated.
02
Drugs
PF-07258669
03
Conditions
unintentional weight loss
Beyond the preview
Go deeper on NCT07086664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07086664.